Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methazolamide for Tumor Oxygenation in Cervical Cancer
NCT00257829Phase 2Withdrawn
- Sponsor
- University of California, Irvine
- Start
- Jul 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of methazolamide in Cervical Cancer (CC), sponsored by University of California, Irvine. Primary endpoint: Feasibility in improving tumor oxygenation at 7 days. Planned start Jul 2004; status: withdrawn.
02
Drugs
methazolamide
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00257829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257829.